| 28th week of 2015 patent applcation highlights part 6 |
| Patent application number | Title | Published |
|---|
| 20150190324 | COSMETIC COMPOSITIONS FOR IMPROVING THE APPEARANCE OF SKIN - The present invention describes methods for improving the appearance of skin, particularly, treating, ameliorating, preventing, delaying, and/or improving one or more signs of aging, by topically applying compositions comprising aryl-thiazole compounds. | 2015-07-09 |
| 20150190325 | CLEANSING AGENT COMPOSITION COMPRISING SULFONATE-TYPE SURFACTANT AND/OR SULFATE-TYPE ANIONIC SURFACTANT AND HETEROCYCLIC COMPOUND - A cleansing agent composition containing
| 2015-07-09 |
| 20150190326 | COSMETIC COMPOSITIONS - Suggested is a cosmetic composition, comprising (a) menthone compounds according to formula (Ia) or (Ib) and (b) at least one oil body or wax, and optionally (c) at least one emulsifier and/or (d) at least one active principle. | 2015-07-09 |
| 20150190327 | PROCESS FOR PREPARING A DERMATOLOGICAL COMPOSITION COMPRISING OLEOSOMES - A method is described for producing an oil-in-water emulsion including oil globules, the mean diameter of which is less than 500 nm and each of which is provided with a lamellar liquid crystal coating, and which are dispersed in an aqueous phase. Each oil globule is individually coated with a unilamellar or oligolamellar layer obtained from at least one lipophilic surfactant, at least one hydrophilic surfactant, and at least one separate anionic surfactant, characterized in that the number of steps in the method is no greater than 5, in that the temperatures used during the different steps are no higher than 75° C., and in that the method requires neither the use of a high-pressure homogenizer nor any pre-emulsification step. | 2015-07-09 |
| 20150190328 | LIQUID CLEANSER COMPRISING STEROL ESTER - Provided is a composition containing a sterol ester, which is an oil poorly soluble in water, and superior in transparency, stability, foaming property, rinsability, skin feel (during rinsing and/or after use), and emollience. A composition containing
| 2015-07-09 |
| 20150190329 | MINERAL-ENZYME COMPLEX FOR STRENGTHENING AND WHITENING TOOTH ENAMEL, ORAL HYGIENE COMPOSITION, AND TOOTHPASTE - The invention relates to the field of cosmetology, namely to mineral-enzyme complexes for tooth enamel strengthening and whitening, and also to compositions for oral hygiene comprising said complex, in particular, to toothpastes and other compositions. The described mineral-enzyme complex for tooth enamel strengthening and whitening is characterized by the fact that it contains calcium hydroxyapatite and tannase with the following component proportions: from 0.2 to 10 parts of tannase per 100 mass parts of calcium hydroxyapatite. The said complex may also additionally contain grapeseed extract. Besides, a variety of compositions for oral hygiene are disclosed that comprise the claimed mineral-enzyme complex. The invention makes it possible to improve consumer properties of the complex and compositions for oral cavity hygiene using the claimed mineral-enzyme complex: cleaning ability, whitening properties, reduction of gum inflammation and gum bleeding, improvement of desensitizing action while retaining remineralizing effect in respect of dental tissues. | 2015-07-09 |
| 20150190330 | DENTAL ADHESIVE COMPOSITION - Dental adhesive composition comprising
| 2015-07-09 |
| 20150190331 | NAIL LACQUER COMPOSITION WITH HYPOSENSITIVITY - The present invention provides a gel polish composition characterized by containing no irritating reactive (meth)acrylate monomer, such as hydroxyethylmethacrylate (HEMA) and ethyl methacrylate (EMA). In the present invention, the gel polish composition comprises at least an aliphatic urethane acrylate oligomer, a polyester acrylate oligomer, a low-irritating acrylate monomer, and a photoinitiator. The gel polish composition possesses low or no irritating effects to skin, exhibits excellent adhesiveness to nails, and is stable in long-term storage at ordinary shelf conditions. | 2015-07-09 |
| 20150190332 | MULTI-LAYER COSMETIC FILMS - Cosmetic compositions are provided, which are capable of forming an immiscible multi-layered composition. Cosmetic compositions according to the invention typically include a first composition comprised of a pH dependent film-forming polymer with a target pH and wherein the pH of the first composition is greater than the target pH, and a second composition having a pH less than or equal to the target pH. The immiscible multi-layered composition enable various optical effects that provide enhance coverage, color trueness and enhanced naturalness. | 2015-07-09 |
| 20150190333 | HAIR COSMETIC - A hair cosmetic composition comprising the following components (A) to (C):
| 2015-07-09 |
| 20150190334 | SHAMPOO COMPOSITION - Disclosed is a shampoo composition comprising a silicone component which comprises a dimethiconol, a blend of dimethicone with surface active block copolymer, and further comprises an aminosilicone. The shampoo can provide improved conditioning benefit. | 2015-07-09 |
| 20150190335 | Silyl Polymeric Benzoic Acid Ester Compounds, Uses, And Compositions Thereof - The present invention relates to organosilicon polymers containing benzoic acid esters in form of particles, process for their preparation, cosmetic or dermatological composition comprising them, as well as their use for protecting a human or animal living body from UV radiation. | 2015-07-09 |
| 20150190336 | FILAGGRIN GENE EXPRESSION PROMOTER - The present invention provides a novel substance that promotes expression of filaggrin gene involved in improvement of the moisture retention function of skin. The inventors of the present invention found that expression of filaggrin gene fluctuates rhythmically over a roughly 24 hour cycle, screened candidate substances based on the time at which expression reaches a maximum following addition of the candidate substance, and identified zanthoxylum extract, 3-(1′-piperidine)propionic acid, geranium oil, cypress oil, rose oil, galvanum oil, pepper oil, basil oil, methyl-o-toluate, methyl anthranilate and dimethyl anthranilate as filaggrin gene expression promoting agents. | 2015-07-09 |
| 20150190337 | COMPOSITION FOR TREATING SKIN PIGMENTATION - The invention relates to a topical composition containing a bilirubin-producing plant extract. In particular, the bilirubin-producing plant extract is obtained from the genus | 2015-07-09 |
| 20150190338 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS - Disclosed is a method of lightening skin or evening skin tone, the method comprising topically applying to skin in need thereof a composition comprising an extract from | 2015-07-09 |
| 20150190339 | Method of Improving Aging Appearance of Skin by Modulation of WIPI-1 - Methods of using WIPI-1 to impart anti-aging benefits to the skin and/or improve skin conditions resulting from reduced autophagy activity. | 2015-07-09 |
| 20150190340 | EYE DROP WITH DIFLUPREDNATE FOR MACULAR EDEMA TREATMENT - The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema. | 2015-07-09 |
| 20150190341 | Liquid Vehicle for Suspension of Undelivered Particles - The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. Additionally or optionally, there is a step of applying a sufficient amount of a liquid to the treatment area after substantial evaporation of the formulation leaves a particle residue on the skin surface. Thereafter, one or more steps of facilitating delivery of particles into a portion of the skin are repeated. Finally, the particles are exposed to a suitable energy activation, thereby providing the desired treatment or clinical outcome. | 2015-07-09 |
| 20150190342 | MULTICOMPARTMENTALIZED MATERIAL FOR THE THERMOSTIMULATED DELIVERY OF SUBSTANCES OF INTEREST, PREPARATION PROCESS AND APPLICATIONS - The present invention relates to a material in the form of solid particles with a diameter varying from 1 μm to 1 cm which are composed of a continuous shell E | 2015-07-09 |
| 20150190343 | ANNELID HAEMOGLOBIN LYOPHILISATION PROCESS - The present invention relates to a lyophilizate comprising at least one globin, one globin protomer or one extracellular hemoglobin of annelids, and a stabilizer chosen from disaccharides, polyols and antioxidants. The present invention also relates to a composition comprising: a solution comprising at least one globin, one globin protomer or one extracellular hemoglobin of annelids, and a stabilizer chosen from disaccharides, polyols and antioxidants. | 2015-07-09 |
| 20150190344 | FORMULATIONS FOR DELIVERING INSULIN - Oral insulin formulations and processes for preparing oral insulin formulations are provided. | 2015-07-09 |
| 20150190345 | Controlled Release Formulations of Lorazepam - Controlled release of lorazepam can provide enhanced dosing options including once daily dosing that provides 24 hour therapeutic effect under steady state conditions. The pharmaceutical composition can provide substantially zero order release and 90% release within 7 to 12 hours in a pharmaceutical dissolution test. The release can be achieved using polyethylene oxide as a matrix polymer. | 2015-07-09 |
| 20150190346 | COMPOSITIONS AND METHODS FOR TREATMENT OF ABNORMAL CELL GROWTH - This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans. | 2015-07-09 |
| 20150190347 | SOLID DRUG TABLETS FOR IMPLANTABLE DRUG DELIVERY DEVICES - A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another. | 2015-07-09 |
| 20150190348 | PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH SUSTAINED RELEASE CHARACTERISTIC AND WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL - A pharmaceutical or nutraceutical composition with a core, an inner coating layer, and an outercoating layer, wherein a pharmaceutical or a nutraceutical active ingredient is contained in the core, one or more salts of alginic acid is contained in the inner coating layer, and one or more water-insoluble polymers or copolymers is contained in the outer coating layer. In the composition, the ratio of the amount of the one or more salts of alginic acid in the inner coating layer is at least 2.5:1 by weight to the amount of the one or more water-insoluble polymers or copolymers in the outer coating layer. | 2015-07-09 |
| 20150190349 | TRANSDERMAL THERAPEUTIC SYSTEM - Multilayer, active substance-containing transdermal therapeutic system (TTS) for releasing active substances via the skin to the human body. | 2015-07-09 |
| 20150190350 | MONOPOLYMER MULTIFUNCTIONAL SEQUENCED CAST POLYURETHANE MATRIX AND PRODUCTION METHOD - The invention relates to a monopolymer multifunctional sequenced cast polyurethane matrix produced simply and efficiently, by sequentially pouring various isocyanate/polyol complex phase solutions successively into a mould with alternating solidification of said phase solutions according to a defined order and respecting the polymerisation stage (after the pot life and before the demoulding time) of the sequence preceding the one being cast, so as to end with the casting of the last phase solution that will go up to the demoulding time thereof and thereby finish the polymerisation of the whole of the matrix. It is loaded, in its “reservoir” sequences, with naturally originating or synthesised transdermally penetrating or volatile active substances. They are medicating and therapeutic, cosmetic, phytosanitary or wellness substances, repellents, attractants, pheromones, biocides, perfumes or deodorants. At least two active substances can be loaded into the same matrix in order to act unidirectionally or in opposite directions. Said matrix is used to form different devices that adhere to the skin or any other surface, in order to deliver at least one substance in a controlled manner. Said devices are patches, patches with a plurality of active substances, replaceable plasters stuck to a textile support, active heel pads and ball pads for shoes, pheromone cards for controlling insects, self-adhesive insecticide attractant cards, or other devices equivalent in terms of structure and function. | 2015-07-09 |
| 20150190351 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-d- ione structural scaffold, their biological activity, and uses thereof - The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof. | 2015-07-09 |
| 20150190352 | USE OF FLUOXETINE IN ANIMALS - The present invention relates to a method for suppressing the libido in livestock and increasing the meat production, wherein fluoxetine or a pharmaceutically acceptable salt, solvate, polymorph, or a racemic mixture thereof is administered to the livestock. | 2015-07-09 |
| 20150190355 | METHOD FOR TREATING AN INFLAMMATION OR LESION CAUSED BY A VIRUS - A method for treating an inflammation or lesion caused by herpes virus, comprising topically applying to said inflammation or lesion a composition comprising or consisting essentially of a C | 2015-07-09 |
| 20150190356 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR RADIATION DAMAGE - An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: | 2015-07-09 |
| 20150190357 | USE OF A CREAM THAT PROTECTS AGAINST THE EFFECTS OF AGGRESSIVE CHEMICAL AGENTS IN CONTACT WITH THE SKIN - The use of an emulsion for protecting the skin against aggressive chemical agents, wherein this emulsion includes at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y) B | 2015-07-09 |
| 20150190358 | COMPOUNDS FROM THE FRUITS OF ACROCOMIA CRISPA AND ACROCOMIA ACULEATA FOR USE AGAINST OXIDATIVE STRESS AND INFLAMMATION - This invention is related to the obtainment of a new active ingredient and its obtaining process from green or ripe fruits of both | 2015-07-09 |
| 20150190359 | STABLE LIPOSOMAL FORMULATIONS FOR OCULAR DRUG DELIVERY - A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F | 2015-07-09 |
| 20150190360 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE - Methods of therapeutic treatment using monomethyl fumarate are disclosed. | 2015-07-09 |
| 20150190361 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES IN A SUBJECT ON CONCOMITANT STATIN THERAPY - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 2015-07-09 |
| 20150190362 | TRANSITION METAL COMPLEXES FOR INHIBITING RESISTANCE IN THE TREATMENT OF CANCER AND METASTASIS - The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is convalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal. | 2015-07-09 |
| 20150190363 | METHODS TO TREAT NEURODEGENERATIVE DISEASES - The present invention is based on the discovery that motor neurons derived from patients with a neuro-degenerative disease have decreased delayed rectifier potassium current and increased persistent sodium current compared to motor neurons derived from control healthy individuals. The present invention is also based on the discovery that the class of compounds known as “potassium channel openers” can be used to treat neurodegenerative diseases, including ALS, Parkinson's disease, Alzheimer's disease, epilepsy, and pain. | 2015-07-09 |
| 20150190364 | SPARC AND METHODS OF USE THEREOF - The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor. | 2015-07-09 |
| 20150190365 | Combination Dosage Forms and Therapies For Supporting Bone Health - Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health. | 2015-07-09 |
| 20150190366 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS - The present invention relates generally to methods for inhibiting neuron apoptosis and necrosis associated with excess glutamate release. | 2015-07-09 |
| 20150190367 | METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRHEA - Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer. | 2015-07-09 |
| 20150190368 | Novel Inhibitors of Arachidonic Acid Formation - The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol. | 2015-07-09 |
| 20150190369 | QUERCETIN-3-GLUCOSIDE AND USES THEREOF - There is described herein a use of quercetin-3-O-β-D-glucoside (Q3G) for increasing the amount of cell surface low-density lipoprotein receptor (LDLR) on a cell and for reducing the amount of functional proprotein convertase subtilisin/kexin type 9 (PCSK9) secreted by the cell, where the Q3G is formulated for administration to the cell, and where the increase in cell surface LDLR and the decrease in secretion of functional PCSK9 is in comparison to the cell not exposed to Q3G. The use may optionally include the treatment of a statin. There is also described a method of reducing plasma cholesterol levels in a patient in need thereof. The method includes treating the patient with a therapeutically effective amount of Q3G and, optionally, a therapeutically effective amount of a statin. | 2015-07-09 |
| 20150190370 | Inhibitors of CD40-TRAF6 Interaction - The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds. | 2015-07-09 |
| 20150190371 | TOPICAL COMPOSITIONS IN THE FORM OF A GEL CONTAINING A PARTICULAR SOLUBILIZED RETINOID - A composition in the form of a gel, preferably hydroglycolic, is described. The composition can include in a physiologically acceptable medium, at least one particular retinoid. Also described, is a method for the preparation thereof and the cosmetic and dermatological use of the same. | 2015-07-09 |
| 20150190372 | MICROCAPSULES CONTAINING RETINOIDS, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME - Microcapsules are described that include a pharmaceutical active agent selected from among retinoids, an anionic hydrophilic polymer (in particular, gum arabic), and a cationic hydrophilic polymer (in particular, type-A gelatin). Also described, are methods for preparing such microcapsules, topical pharmaceutical compositions including such microcapsules, and dermatological uses thereof. | 2015-07-09 |
| 20150190373 | Method of Treating Diabetes Mellitus - The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject. | 2015-07-09 |
| 20150190374 | FORMULATIONS OF CYCLOPROPANECARBOXYLIC ACID -AMIDE - Pharmaceutical compositions and single unit dosage forms of {2-[(IS)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindo1-4-yl}-amide, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease. | 2015-07-09 |
| 20150190375 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL - Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention. | 2015-07-09 |
| 20150190376 | NEW INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING - The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment. The present invention further relates to a pharmaceutical composition or a commercial package comprising the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling. | 2015-07-09 |
| 20150190377 | NEURONAL REGENERATION - There are provided, inter alia, methods and compositions useful for neuronal regeneration, including methods for increasing expression of a regeneration-associated marker gene, and methods for increasing neuronal growth. | 2015-07-09 |
| 20150190378 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase - The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives. | 2015-07-09 |
| 20150190379 | BAX-Activating Cancer Therapeutics - The pro-apoptotic Bcl-2 protein Bax initiates apoptosis in almost all apoptotic paradigms. Agents facilitating disruptive Bax insertion into mitochondrial membranes have potential as cancer therapeutics. Small molecule compounds associating with the hydrophobic groove of the pro-apoptotic Bcl-2 protein Bax have been identified and found to promote Bax-dependent, but not Bak-dependent, apoptosis. The compounds alter Bax protein stability in vitro and promote Bax insertion into mitochondria, leading to Bax-dependent mitochondrial outer membrane permeabilization and apoptosis. The compounds activating the pro-apoptotic Bcl-2 protein Bax inhibit the growth of tumors by inducing apoptosis. Pharmaceutical compositions comprising the compounds that activate Bax and induce Bax-dependent apoptosis are useful as anti-cancer therapeutic agents alone or with other anti-cancer agents. Methods for inducing apoptosis and for treating cancer involve administering the compounds to a patient in need thereof. | 2015-07-09 |
| 20150190380 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CERTAIN HEMATOLOGIC DISORDERS - Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed. | 2015-07-09 |
| 20150190381 | SNS-595 AND METHODS OF USING THE SAME - The present invention relates to SNS-595 and methods of treating cancer using the same. | 2015-07-09 |
| 20150190382 | TREATMENT OF SUNBURN USING ANALGESICS AND ANTIHISTAMINES - Combination compositions and kits comprising an analgesic and an antihistamine are provided as well as methods of use in treating sunburn. | 2015-07-09 |
| 20150190383 | HAIR CARE COMPOSITION WITH ANALGESIC - A hair detangling composition includes a conditioning material, a lubricant, a scent, and an anesthetic. | 2015-07-09 |
| 20150190384 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA - Disclosed herein are compounds, compositions and methods of their use to treat HIV/AIDS disease in a subject in need thereof wherein the compositions comprise small molecule inhibitors that inhibit viral preparation or viral recruitment of human tRNA3Lys. | 2015-07-09 |
| 20150190385 | Thiazolidinedione Analogues - The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes. | 2015-07-09 |
| 20150190386 | METHODS FOR TREATING MULTIPLE MYELOMA WITH 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL) PIPERIDINE-2,6-DIONE IN COMBINATION WITH SECOND ACTIVE AGENTS - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2015-07-09 |
| 20150190387 | TRICYCLIC ALKENE DERIVATIVES AS HIV ATTACHMENT INHIBITORS - Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors. | 2015-07-09 |
| 20150190388 | PHARMACEUTICAL COMPOSITION OF MOXIFLOXACIN HYDROCHLORIDE AND PREPARATION METHOD - The subject of the present invention is a method for preparing a pharmaceutical moxifloxacin hydrochloride composition in solid form, which comprises mixing a moxifloxacin hydrochloride having a water content of less than 2% by weight with one or more pharmaceutically acceptable excipients. The subject of the invention is also a pharmaceutical composition obtainable by this method. | 2015-07-09 |
| 20150190389 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER - The present disclosure is directed to compounds of the structure (X): | 2015-07-09 |
| 20150190390 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding. Cassette (“ABC”) transporters or fragments thereof, including. Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2015-07-09 |
| 20150190391 | INHIBITORS OF NKX2.5 FOR VASCULAR REMODELLING - The invention relates to vascular remodelling, and to the treatment of conditions that are characterised or caused by inappropriate vascular remodelling. The invention also extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. | 2015-07-09 |
| 20150190392 | Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof - The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed. | 2015-07-09 |
| 20150190393 | USE OF OXYCODONE FOR TREATING VISCERAL PAIN - It is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Visceral pain and especially acute (i.e. non-chronic) visceral pain can be effectively treated by administering oxycodone at a dosage which is lower than the corresponding dosage of the other opioids like morphine. | 2015-07-09 |
| 20150190394 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN - The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain. | 2015-07-09 |
| 20150190395 | Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. | 2015-07-09 |
| 20150190396 | TREATMENT OF TYPE I AND TYPE II DIABETES - The present invention provides methods of treating Type I or Type II diabetes in a mammal by administering an effective amount of insulin and an effective amount of a phenoxypyrimidinone compound to the mammal in need of such treatment, and formulations for carrying out the methods. | 2015-07-09 |
| 20150190397 | Treatment of Cancers Expressing p95 ErbB2 - The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with 5 either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2 inhibitor, and methods of treating such patients. | 2015-07-09 |
| 20150190398 | POLYMERIC NANOPARTICLES IN A THERMOSENSITIVE GEL FOR COITAL-INDEPENDENT VAGINAL PROPHYLAXIS OF HIV - An antiretroviral composition that gels upon heating and can be administered prophylactically prior to exposure to a retrovirus following sexual intercourse, and methods of using the same. | 2015-07-09 |
| 20150190399 | NEW DIFFERENTIAL-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE PRINCIPLES - This invention relates to a differential release formulation containing an angiotensin-II receptor antagonist, a calcium channel blocker and a diuretic, wherein the said pharmaceutical composition allows the sequential administration of the active principles in a single dose based on the treatment needs. | 2015-07-09 |
| 20150190400 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION - This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele. | 2015-07-09 |
| 20150190401 | ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS - The disclosure relates to selected administration routes for CNS (central nervous system) therapeutics and highly soluble salts, solutions, emulsions or powder formulations thereof, having optimal brain delivery due to the mode of administration and the chemical nature of the compounds of the disclosure. | 2015-07-09 |
| 20150190402 | SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer. A concentration-enhancing polymer is water soluble or readily disperse in water, so that when the polymer is placed in water or an aqueous environment (e.g. fluids in the gastrointestinal (GI) tract or simulated GI fluids), the solubility and/or bioavailability of suvorexant is increased over the solubility or bioavailability in the absence of the polymer. | 2015-07-09 |
| 20150190403 | USE OF OLANZAPINE IN ANIMALS - The present invention relates to a method for suppressing the libido in livestock and increasing the meat production, wherein olanzapine or a pharmaceutically acceptable salt, solvate, polymorph, or a racemic mixture thereof is administered to the livestock. | 2015-07-09 |
| 20150190404 | TREATING SEIZURES USING ICE INHIBITORS - This invention relates to methods and compositions for treating or preventing seizures. | 2015-07-09 |
| 20150190405 | Combination of Azelastine and Fluticasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 2015-07-09 |
| 20150190406 | Steroidal Compositions - Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein. | 2015-07-09 |
| 20150190407 | METHODS FOR TREATMENT OF POSTOPERATIVE INFLAMMATION WITH REDUCED INTRAOCULAR PRESSURE - Methods of treating a subject after ocular surgery are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least one corticosteroid or an ophthalmically acceptable salt thereof in an ophthalmically acceptable vehicle that can provide a sustained release of the at least one corticosteroid or an ophthalmically acceptable salt thereof. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks. | 2015-07-09 |
| 20150190408 | METHODS FOR TREATING BACTERIAL INFECTION - The present disclosure relates to molecules which function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as | 2015-07-09 |
| 20150190409 | TOPICAL TETRACYCLINE COMPOSITIONS - A topical therapeutic hydrophobic breakable composition includes a carrier comprising, (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force. | 2015-07-09 |
| 20150190410 | USE OF CREATINE AND PHOSPHOCREATINE IN THE TREATMENT OF EPILEPSY AND ALCOHOL ADDICTION - The present invention relates to neurological disorders and treatment of epilepsy, seizures and alcoholism. In one embodiment, the present invention provides a method of treating the frequency of epileptic seizures in an subject by administering a therapeutically effective dosage of a composition comprising creatine and/or phosphocreatine. In another embodiment, the present invention provides a method of treating alcoholism by administering a composition comprising creatine and/or phosphocreatine. | 2015-07-09 |
| 20150190411 | ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL - The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+−)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof. | 2015-07-09 |
| 20150190412 | Pharmaceutical composition for the treatment of Lyme-borreliosis - The present invention provides for a composition to be applied in the treatment of borreliosis and a kit. The composition includes four groups of components with which group A) the components 1000-5000 mgs Cat's Claw, 1000-3000 mgs Krill Oil or Kalamarine Oil or combinations of it, 200-600 mgs Magnesium Malate, 3000-5000 mgs ester C, 100-300 mgs Alpha-Lipoic Acid, 25-75 mgs Pyridoxyl-5-Phosphate (vitamin B6), 6000-14000 IU Cholecalciferol (vitamin D3), 2000-4000 mgs He Shou Wu, 1200-2500 mgs Purple Clovers Tea, 10-50 mls parsley juice, the group B) 2000-4000 mgs Monolaurine, 400-800 mgs N-Acetylcysteine, 100-300 mgs Hyaluronic acid with BioCell collagens II, 1-5 drops Teasel Root, the group C) 10-70 drops Spilanthes Acmella and the group D) 500-1500 μg Cyancobalamin (vitamin B12). The composition and the kit is suitable to be applied in the treatment of borreliosis with which the components of the group A) are administered once daily, those of the group B) twice daily, those of the group C) three times daily and that of the group D) every 14 days. | 2015-07-09 |
| 20150190413 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLADDER CANCER - Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent. | 2015-07-09 |
| 20150190414 | AGENT FOR AMELIORATING BRAIN HYPOFUNCTION - Provided are effective and highly safe agents, medicaments and the like for ameliorating various disorders caused by brain hypofunction. Also provided is a preventing or ameliorating agent for brain hypofunction containing N-acetyl-D-mannosamine, a pharmaceutical composition for preventing, ameliorating or treating disorders due to brain hypofunction, containing an effective amount of N-acetyl-D-mannosamine and a pharmaceutically acceptable carrier, and a food comprising N-acetyl-D-mannosamine added thereto. | 2015-07-09 |
| 20150190415 | NOVEL COMPOSITIONS COMPRISING MACROLIDE AND TETRACYCLINE AND THEIR USES - The present invention provides for methods, compositions, and kits pertaining to the treatment of various diseases associated with inflammation. In various aspects, the invention provides methods and compositions comprising an effective amount of a macrolide and an effective amount of a tetracycline. | 2015-07-09 |
| 20150190416 | FILAGGRIN PRODUCTION PROMOTER, THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH REDUCTION IN PRODUCTION OF FILAGGRIN, AND METHOD FOR SCREENING FOR SAID THERAPEUTIC AGENT - The present invention provides a highly effective substance having a filaggrin production-promoting action. The present invention also provides a therapeutic agent useful for treating a skin disease, in particular, atopic dermatitis associated with reduced filaggrin production. As a result of intensive studies on a filaggrin production promoter, it has been found that A) an N-quinolylbenzamide derivative (Compound 1), B) ivermectin (Compound 2), or C) a phenylalaninamide derivative (Compound 3) promotes production of filaggrin in skin and satisfactorily improves a water retention ability and barrier function of the stratum corneum. The present invention relates to a filaggrin production promoter containing a certain N-quinolylbenzamide derivative or a pharmaceutically acceptable salt thereof as an active ingredient. | 2015-07-09 |
| 20150190417 | CHEWABLE FORMULATION - The present invention relates to a chewable formulation for delivering a nutritional or pharmaceutically active agent to an animal target. The chewable formulation comprises a nutritional ingredient or an effective amount of a pharmaceutically active agent, and a plasticiser. The chewable formulation is formed by extrusion and the formulation contains substantially no unbound water, nor is any water added in the manufacturing process. The present invention also relates to a method of manufacturing a shelf stable chewable formulation which comprises mixing the nutritional or pharmaceutically active agent with a fat, lipid or fat and lipid to obtain a first composition, adding one or more plasticizers to the first mixture to obtain a second composition, extruding the second composition at a temperature sufficient to melt the fat and lipid, and allowing the extruded second composition to cool to room temperature thereby providing the chewable formulation. | 2015-07-09 |
| 20150190418 | COMBINATION PREPARATIONS OF 3-N-FORMYL HYDROXY AMINO PROPYL PHOSPHONIC ACID DERIVATIVES OR 3-N-ACETYL HYDROXY AMINO PROPYL PHOSPHONIC ACID DERIVATIVES TOGETHER WITH SPECIAL PHARMACEUTICAL ACTIVE INGREDIENTS - The invention relates to pharmaceutical combination preparations for use in the therapeutical and prophylactic treatment of bacterial and parasitic infections, especially malaria. The inventive preparations contain as the active substances 3-N-formyl-hydroxylaminopropyl phosphonic acid derivatives or 3-N-acetylhydroxylaminopropyl phosphonic acid derivatives combined with other pharmaceutical active agents. | 2015-07-09 |
| 20150190419 | METHOD TO TREAT OR PREVENT HERPESVIRUS INFECTIONS - Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian Akt. | 2015-07-09 |
| 20150190420 | Method of Cross-Linking Hyaluronic Acid with Divinylsulfone - The present invention relates to methods of producing a homogenous hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with divinylsulfone (DVS), said method comprising the steps of (a) providing an alkaline solution of hyaluronic acid, or salt thereof; (b) adding DVS to the solution of step (a), whereby the hyaluronic acid, or salt thereof, is crosslinked with the DVS to form a gel; (c) treating the gel of step (b) with a buffer, wherein the gel swells and forms a hydrogel comprising hyaluronic acid, or salt thereof, crosslinked with DVS. | 2015-07-09 |
| 20150190421 | POLOXAMERS FOR THE IMPROVEMENT OF RESPIRATORY FUNCTION - Methods for treating or preventing a respiratory deficiency associated with a diaphragm muscle deficiency in a subject are provided, the method comprises administering to the subject in need thereof, a therapeutically effective amount of a poloxamer, for example, poloxamer P-188. | 2015-07-09 |
| 20150190422 | Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications - The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided. | 2015-07-09 |
| 20150190423 | METHOD OF POTENTIATING AN ANTITUMOR IMMUNE RESPONSE - A method of inducing autophagy in a cell is achieved by contacting the cell with graphene oxide (GO) in an amount effective to induce autophagy in the cell, wherein the cell expresses at least one of TLR-4 (Toll-like receptor 4) and TLR-9 (Toll-like receptor 9). Differences between autophagy triggered by GO and other conventional agonists such as rapamycin have been observed. GO may activate autophagy in some cells that may not be triggered by rapamycin. The cell reveals no apparent apoptosis after treatment of the graphene oxide. A method of method of potentiating an antitumor immune response is also herein provided. | 2015-07-09 |
| 20150190424 | GLUCOSALINE MAINTENANCE SOLUTION FOR PEDIATRIC PARENTERAL ADMINISTRATION - A solution for electrolyte replacement, suitable for parenteral administration and pediatric use, particularly useful in hospital contexts for maintaining the hydro-electrolyte balance, in particular for preventing iatrogenic hyponatremia, which allows to provide a proper potassium and sodium supply for the electrolyte replacement, and at the same time, it retains proper glucose levels, without inducing acidosis is disclosed. | 2015-07-09 |
| 20150190425 | MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USE - The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions. | 2015-07-09 |
